Drug Database
FA

Factor IX (AlphaNine SD / AlphaNine)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · F9 · 细胞治疗

什么是 Factor IX?

Factor IX 是一种细胞治疗,由Mitsubishi Tanabe Pharma Corporation研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名AlphaNine SD, AlphaNine
公司Mitsubishi Tanabe Pharma Corporation
药物类别细胞治疗
分子靶点F9
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

Factor IX 作用于 1 个分子靶点:

F9coagulation factor IX (P19, F9 p22)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

Factor IX 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersExtravasation blood✓ Approved
Congenital, familial and genetic disordersFactor IX deficiency✓ Approved
Vascular disordersHaemorrhage✓ Approved

相关研究文献

PubMedMolecular nutrition & food research2026-08-05

Heat-Killed Bifidobacterium longum ZFML0012 Alleviates Rheumatoid Arthritis via Gut-Joint Axis Regulation: Remodeling Microbiota, Boosting SCFAs/L-Glutamine, and Rebalancing Th17/Treg Immunity.

Yang Tiantian T, Zhang Yubin Y, Huang Yingjie Y, Xi La et al.

Rheumatoid arthritis (RA) is an autoimmune disease closely associated with gut microbiota dysbiosis. Amid growing interest in microbial-derived therapeutics, postbiotics, defined as preparations of nonliving microorganisms and/or their components conferring host benefits, have emerged as candidates. However, the immunomodulatory potential of Bifidobacteria postbiotics in RA remains unexplored. This study investigated the effects of heat‑killed Bifidobacterium longum ZFML0012 (HK‑B. longum) on RA and its underlying mechanisms using in vitro and in vivo models. In LPS-induced cells, HK-B. longum significantly suppressed the expression of pro-inflammatory cytokines such as IL-1β and TNF-α while promoting the anti-inflammatory factor IL-10. In collagen-induced arthritis (CIA) mice, it reduced arthritis scores, joint swelling, and bone erosion. Mechanistically, HK-B. longum remodeled gut microbiota, increased SCFAs (acetate and butyrate), and particularly upregulated the immunomodulatory metabolite L-Glutamine in both gut and serum. In vitro experiments confirmed that L-Glutamine inhibited TNF‑α‑induced inflammation, abnormal proliferation, and migration in MH7A synovial cells. Meanwhile, HK‑B. longum regulated the T helper cell 17/Regulatory T cell (Th17/Treg) immune imbalance, modulated local inflammatory factors, and restored the osteoprotegerin/receptor activator of nuclear factor‑κB ligand (OPG/RANKL) ratio in joints. These findings provide new evidence for using postbiotics to alleviate RA through gut-joint axis regulation.

PMID 42554007
阅读全文 →
PubMedFrontiers in psychology2026-08-05

The cross-cultural adaptation and psychometric evaluation of the Chinese version of the stigma scale for caring for individuals with sexually transmitted infections (STISS)-student version: a translation and validation study.

Shi Jiahao J, Lin Youbei Y, Li Chuang C, Gong Yinghui Y et al.

Stigmatization of patients with sexually transmitted infections remains prominent, whereas previous measurement tools have mostly focused on single-disease populations and lack a systematic assessment of the broader population of individuals with sexually transmitted infections. To translate the Stigma Scale for Caring for Individuals with Sexually Transmitted Infections (STISS) - Student Version and evaluate its reliability and validity among nursing students in China. This study recruited 413 nursing students through convenience sampling based on Kendall's sample size estimation method. The original version of the scale was translated according to the Brislin guidelines, and content validity and the feasibility of the translation were validated through expert consultation. Structural validity was assessed using exploratory factor analysis and confirmatory factor analysis. Reliability was tested using internal consistency reliability. The Chinese version of the STISS scale demonstrated good psychometric properties. The Cronbach's alpha coefficient was 0.921. The four-factor exploratory factor model explained 58.947% of the total variance, indicating a robust factor structure. Confirmatory factor analysis showed the following fit indices: χ 2/df = 1.078; RMSEA = 0.019; CFI = 0.994; TLI = 0.993; GFI = 0.927; AGFI = 0.907. All indices were within acceptable ranges, and both convergent validity and discriminant validity were adequately confirmed. This study strictly followed the Brislin translation model and successfully introduced the STISS scale, which demonstrated strong reliability and validity within the Chinese cultural context. It is highly suitable for measuring the level of stigmatization of individuals with sexually transmitted infections among nursing students in China.

PMID 42553320
阅读全文 →
PubMedJournal of peptide science : an official publication of the European Peptide Society2026-08-05

Peptide Therapeutics for Solid Tumors: Functional Classes, AI-Enhanced Discovery and Clinical Advances.

Liang Jinqiu J, Tang Xiaochuan X, Li Haoqi H, Fang Yan Y et al.

Solid tumors, the most prevalent form of malignancy, pose therapeutic challenges distinct from hematologic malignancies due to their complex biology, including high tumor heterogeneity, a dense extracellular matrix (ECM), an immunosuppressive tumor microenvironment (TME), and multifaceted drug resistance. Peptide drugs have emerged as a focal point in precision oncology, combining the deep tissue penetration of small molecules with the high target specificity, low immunogenicity, and sequence designability of antibodies. This review systematically summarizes advancements in peptide-based therapeutics for solid tumors from 2020 to 2025. These agents are categorized by function into five classes: tumor-homing peptides, surface receptor antagonist/inhibitory peptides, interfering peptides, peptide vaccines, and cell-penetrating peptides as delivery tools. We also highlight the transformative role of artificial intelligence (AI) in peptide design and discovery. Finally, we discuss outcomes from clinical trials of peptide drugs in solid tumors, underscoring their potential as multifunctional agents in this setting.

PMID 42552640
阅读全文 →
PubMedPalliative medicine2026-08-05

Adaptation and psychometric evaluation of the Integrated Palliative care Outcome Scale for Neurological conditions (IPOS-Neuro) in Chinese.

Chan Lily Man Lee LML, Choi Edmond Pui Hang EPH, Lam Wendy Wing Tak WWT, Chan Koon Ho KH et al.

Palliative care has been advocated to improve symptom burden and quality of life among people with progressive neurological diseases. However, validated palliative care outcome measures for neurological conditions remain limited in non-Western settings. To translate, adapt and psychometrically evaluate the Integrated Palliative care Outcome Scale for Neurological conditions (IPOS-Neuro) among people with progressive neurological diseases in Hong Kong. The traditional Chinese version of IPOS-Neuro was developed through forward-backward translations, cognitive debriefing interviews, and expert review. Psychometric properties were evaluated by examining factor structure, convergent validity, concurrent validity, internal consistency, and test-retest reliability. Comparator instruments included Palliative Care Outcome Scale, Hospital Anxiety and Depression Scale, and EQ-5D-5L. Two hundred and ten adults with progressive neurological diseases recruited from regional neurology outpatient clinics and patient support groups in Hong Kong. Confirmatory factor analysis supported the three-factor structure (Physical Symptoms, Emotional Symptoms, and Communication/Practical Issues) with acceptable fit indices. IPOS-Neuro showed good internal consistency (Cronbach's alpha = 0.93), strong concurrent validity with Palliative Care Outcome Scale (r = 0.74), moderate convergent validity with EQ-5D-5L index (r = -0.51) and Hospital Anxiety and Depression Scale (r = 0.56), and excellent test-retest reliability (intraclass correlation coefficient = 0.99). Additional exploratory factor analysis identified a new clinically-meaningful nine-factor model: psychosocial problems and symptom dimensions related to fatigue, motor, gastrointestinal, oral and sensory, cognitive, sexual, bowel, and non-motor issues. The traditional Chinese version of IPOS-Neuro showed promising psychometric properties for assessing palliative care needs in progressive neurological diseases. Future validation in larger and diverse neurological disease samples is warranted.

PMID 42552883
阅读全文 →
PubMedClinical case reports2026-08-05

Alpha-Mannosidosis in a 3.5-Year-Old Girl: A Case Report.

Bonilla Fornes Samuel S, Mendez Perez Maria Pilar MP, Torres Diaz Marta M, Sanchez Gutierrez Maria Eugenia ME et al.

Alpha-mannosidosis is a rare lysosomal storage disease caused by a deficiency of the enzyme alpha-mannosidase. It manifests as a continuous spectrum of signs and symptoms characterized by dysmorphic features, skeletal abnormalities, delayed psychomotor and speech development, impaired hearing, and psychiatric involvement. When suspected, alpha-mannosidosis must be confirmed by biochemical and molecular testing, namely, assessment of blood levels of alpha-mannosidase in leukocytes or fibroblasts and Sanger or next-generation sequencing of the MAN2B1 gene. The disease must be diagnosed and treatment started as quickly as possible, since the long-term prognosis for untreated patients is very poor. Enzyme replacement therapy (ERT, human recombinant alpha-mannosidase) has replaced allogeneic stem cell transplant as the mainstay of therapy, thus improving disease-related outcomes with, for example, reduced serum oligosaccharide levels, greater functional capacity, and improved quality of life, all with a good safety profile. We report the seventh case of alpha-mannosidosis in Spain. The patient was a 3.5-year-old girl assessed in the clinical genetics department for developmental delay and marked dysmorphic features (trigonocephaly, exophthalmos, hypertelorism, and a flat nasal bridge). Radiography revealed shortening and thickening of the long bones, as well as metopic and coronal synostosis. Craniosynostosis was treated with surgery. Assessment of alpha-mannosidase revealed complete absence of enzymatic activity. Genetic analysis revealed the homozygous pathogenic variant of MAN2B1, c.2248C>T, which is associated with alpha-mannosidosis. ERT is the only currently available pharmacological option for treating children with mild-to-moderate alpha-mannosidosis. Without ERT, patients' quality of life would be impaired, and their prognosis would worsen significantly.

PMID 42553539
阅读全文 →
PubMedVascular specialist international2026-08-05

Late Complete Endograft Occlusion After Endovascular Aneurysm Repair Successfully Treated With Unilateral Endograft Relining and Femoro-femoral Bypass: A Case Report.

Suno Kenichiro K, Yamamoto Mika M, Uchiyama Hiroki H, Masuda Takahiko T et al.

Complete endograft occlusion involving the main body and both limbs after endovascular aneurysm repair (EVAR) is rare, and the optimal treatment remains unclear. We report an 85-year-old male with late complete endograft occlusion after EVAR for an abdominal aortic aneurysm. Computed tomography (CT) showed complete thrombotic occlusion extending from just below the renal arteries to both iliac limbs and distally to the level of the external iliac arteries. A hybrid procedure was performed. After proximal recanalization under right renal artery protection, thrombectomy was performed through the left groin. Next, unilateral endograft relining was carried out using Ovation iX limbs, followed by femoro-femoral bypass. Postoperative CT confirmed patency of the relined limb, femoro-femoral bypass, and left external iliac artery reconstruction, with preserved bilateral renal perfusion. The ankle-brachial index improved from 0.58/0.49 to 0.95/0.88. Hybrid revascularization based on unilateral inflow reconstruction may be an effective option for selected patients with this rare complication.

PMID 42552983
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Factor IX